Skip to main content
Clinical Trials/NCT03035799
NCT03035799
Completed
Not Applicable

A Randomized Trial Comparing Two Types of Diets on Psychological and Gastrointestinal Symptoms

Johns Hopkins University1 site in 1 country40 target enrollmentApril 24, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Irritable Bowel Syndrome
Sponsor
Johns Hopkins University
Enrollment
40
Locations
1
Primary Endpoint
Vitality
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This pilot study proposes to gain a better understanding of the health benefits of the popular "paleo-diet" in patients with irritable bowel syndrome (IBS) and explore underlying mechanisms of benefit.

Detailed Description

In the proposed study, the primary hypothesis is that, compared with a customary diet, consumption of a paleo-diet will improve psychological and gastrointestinal symptoms in patients with irritable bowel syndrome. Investigators also hypothesize consumption of the Paleolithic diet will result in decreased intestinal permeability, decreased inflammatory markers, and changes in the gut microbiome and microbiologic profiles.

Registry
clinicaltrials.gov
Start Date
April 24, 2018
End Date
April 1, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with mild to moderate Irritable Bowel Syndrome (IBS) and mild to moderate anxiety or depression
  • Other causes of bowel symptoms excluded to the satisfaction of the Study Team
  • Age at least 18 years at initial screening visit
  • Patients who are able to sign and understand the study's informed consent form
  • Patients able to complete all screening evaluations and procedures

Exclusion Criteria

  • Patients in inpatient hospital care
  • Severe or refractory bowel or psychological symptoms
  • Current consumption of a Paleolithic diet
  • Known Celiac disease
  • Uncontrolled thyroid disease as indicated by an abnormal thyroid stimulating hormone (TSH) level
  • Uncontrolled diabetes as indicated by a HbA1c equal to 6.5 or greater
  • Patients unable to speak English
  • Inability to obtain informed consent
  • Pregnant or nursing women
  • Any condition, which in the opinion of the investigator, would interfere with study requirements

Outcomes

Primary Outcomes

Vitality

Time Frame: The change between baseline and 4 weeks (post-intervention).

Vitality as measured on the vitality subscale of the short form health survey (SF36). This instrument assesses vitality (energy level and fatigue) and is a subscale of SF36, a general health survey designed for use in clinical practice and research, health policy evaluation and general population surveys. The Vitality Subscale score is determined by responses to 4 items: Did you feel full of life? Did you have a lot of energy? Did you feel worn out? Did you feel tired? The lower the score the more disability. The higher the score the less disability.

Secondary Outcomes

  • Anxiety(The change between baseline and 4 weeks (post-intervention).)
  • Depression(The change between baseline and 4 weeks (post-intervention).)
  • Activity level(The change between baseline and 4 weeks (post-intervention).)
  • Gastrointestinal symptoms(The change between baseline and 4 weeks (post-intervention).)
  • Visceral sensitivity(The change between baseline and 4 weeks (post-intervention).)
  • Overall health status (Short Health Scale)(The change between baseline and 4 weeks (post-intervention).)
  • Overall health status (EQ-5D)(The change between baseline and 4 weeks (post-intervention).)

Study Sites (1)

Loading locations...

Similar Trials